Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CTSS drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CTSS Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View CTSS Products |
| Gene Delivery | CTSS Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View CTSS Products |
| Benchmark Ab | Anti-CTSS Recombinant Antibody Sequence-verified clinical benchmark antibody for positive control. |
View CTSS Products |
| Validator | CTSS siRNA Set For knockdown verification and target validation. |
View CTSS Products |
| Related Target A | CD74 The primary physiological substrate of CTSS; critical for MHC II antigen presentation assays. |
View CD74 Products |
| Related Target B | CTSB Lysosomal cysteine protease used for selectivity and counter-screening assays. |
View CTSB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cathepsin Family Selectivity | Human CTSS, CTSB, and CTSL homolog panel proteins strictly verified by mass spectrometry and sequence analysis. |
| pH-Dependent Activity Profiling | HEK293 expressed CTSS preserving native post-translational modifications for physiological pH stability assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CTSS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CTSS therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum protease inhibitors to highly selective small molecules and monoclonal antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting autoimmune diseases such as Sjögren's syndrome and systemic lupus erythematosus (SLE), as well as modulating the tumor microenvironment in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Astellas, Medivir | Sjögren's Syndrome, Lupus | Selectivity Assay (Need Mutant vs WT Proteins) |
| Monoclonal Antibodies | Roche (RG7212) | Solid Tumors, Autoimmune | Epitope Mapping (Need high-purity ECD-Fc) |
| Targeted Degraders (PROTAC) | Academic Institutes | Oncology | Heterodimer Validation (Need Cross-reactive Abs) |